Tag: global neurological disorder drugs market

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Neurological Disorder Drugs Market Set To Climb From $94.49 Billion In 2026 To $116.26 Billion By 2030

The neurological disorder drugs market has experienced substantial growth in recent years. It is forecast to expand from $89.24 billion in 2025 to $94.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The market’s growth during the historical period is attributable to several factors, including the escalating prevalence of epilepsy and neurodegenerative diseases, the global population’s aging, the sustained use of symptomatic neurological drugs, the broadening scope of hospital-based neurological care, and enhanced diagnosis rates for neurological disorders.

The neurological disorder drugs market is anticipated to experience substantial growth in the upcoming years, projected to reach $116.27 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.3%. This expected expansion during the forecast period can be attributed to advancements in neurological drug development pipelines, the increasing burden of Alzheimer’s and Parkinson’s disease, enhanced access to neurological care in emerging markets, a rising demand for personalized neurology treatments, and the broader availability of homecare and outpatient neurological therapy. Prominent trends for the forecast period include the increasing adoption of disease-modifying neurological therapies, a heightened focus on early diagnosis and long-term disease management, a greater demand for combination drug therapies, the expansion of oral and home-based neurological treatments, and a stronger emphasis on symptom management and improving patients’ quality of life.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=26822203&type=smp&name=Neurological%20Disorder%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurological Disorder Drugs Market Demand Drivers Opening New Revenue Streams

The expanding occurrence of neurological diseases is anticipated to boost the growth of the neurological disorder drugs market in the future. Neurological disorders are defined as conditions impacting the brain, spinal cord, and nerves, resulting from structural, biochemical, or electrical irregularities, which manifest in diverse symptoms. The rise in these diseases is linked to an aging global population and heightened exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are crucial for handling these intricate conditions, providing symptom alleviation, decelerating disease progression, and enhancing long-term patient outcomes. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Consequently, the increasing prevalence of neurological disease is stimulating the expansion of the neurological disorder drugs market.

Neurological Disorder Drugs Market Segment Analysis: What Are The Core Market Categories?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Neurological Disorder Drugs Market Trends Powering Strategic Industry Growth

Key companies within the neurological disorder drugs sector are prioritizing the development of innovative solutions, such as Ocrelizumab-based therapies, to enhance treatment efficacy, improve patient outcomes, and broaden therapeutic alternatives for individuals living with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody specifically designed to target CD20-positive B cells, thereby aiding in the reduction of disease activity and slowing progression in both relapsing and primary progressive types of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical corporation, obtained regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), which is an approximately 10-minute subcutaneous injection administered twice-yearly. This approval marked the very first subcutaneous Ocrevus formulation authorized for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is intended to boost convenience, expand access to the treatment, and improve clinical workflow efficiency by offering a faster, non-intravenous administration method.

Neurological Disorder Drugs Market Top Companies Driving Competitive Growth

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

View The Full Neurological Disorder Drugs Market Report:

https://thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurological Disorder Drugs Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Neurological Disorder Drugs Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for neurological disorder drugs has experienced robust expansion in recent years. Projections indicate it will increase from $89.24 billion in 2025 to $94.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.9%. This historical growth has been driven by several factors, including a growing incidence of epilepsy and neurodegenerative conditions, an aging worldwide population, the prolonged utilization of symptomatic neurological medications, the broadening of hospital-based neurological services, and higher rates of diagnosis for neurological disorders.

The market for neurological disorder drugs is projected to experience robust expansion in the coming years, reaching an estimated value of $116.27 billion by 2030, with a compound annual growth rate (CAGR) of 5.3%. This growth during the forecast period is driven by several key factors, including progress in neurological drug development pipelines, a rising prevalence of Alzheimer’s and Parkinson’s diseases, improved access to neurological care in emerging markets, an increased need for personalized neurology treatments, and the expansion of homecare and outpatient neurological therapies. Among the prominent trends shaping the forecast period are the increasing uptake of disease-modifying neurological therapies, a heightened focus on early detection and long-term disease management, a growing demand for combination drug approaches, the development of oral and home-based neurological treatments, and a greater emphasis on symptom control and enhancing patients’ quality of life.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Neurological Disorder Drugs Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising incidence of neurological conditions is anticipated to drive expansion in the neurological disorder drugs market in the coming years. These disorders impact the brain, spinal cord, and nerves due to structural, biochemical, or electrical irregularities, resulting in a range of symptoms. This increase is fueled by an aging global population and heightened exposure to environmental, metabolic, and lifestyle risks. Neurological disorder drugs are vital for managing these complex illnesses, providing symptom relief, decelerating disease advancement, and enhancing long-term patient outcomes. For example, a September 2024 projection from the Australian Institute of Health and Welfare, a government agency in Australia, indicates that dementia cases in the country are expected to more than double from 2023 to 2058, climbing from roughly 411,100 to 849,300, with about 315,500 men and 533,800 women impacted. Consequently, the growing frequency of neurological diseases is propelling the neurological disorder drugs market forward.

Neurological Disorder Drugs Market Segments: Where Are The Largest Growth Opportunities?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Neurological Disorder Drugs Market Industry Trends: What Changes Are Reshaping Demand?

Key players in the neurological disorder drugs market are concentrating on creating advanced solutions, particularly those based on Ocrelizumab, to boost treatment effectiveness, improve patient results, and broaden therapeutic choices for people with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that targets CD20-positive B cells, which helps decrease disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For example, in September 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, secured regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly subcutaneous injection that takes about 10 minutes, marking the first subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This improved delivery method aims to enhance convenience, increase therapy accessibility, and support clinical workflow efficiency by providing a faster, non-intravenous administration option.

Neurological Disorder Drugs Market Major Participants And Competitive Dynamics

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Neurological Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neurological Disorder Drugs Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Neurological Disorder Drugs Market?

The market for neurological disorder drugs has seen robust expansion in recent times. This market is projected to expand from $89.24 billion in 2025 to $94.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. Factors contributing to its historical growth include an increasing incidence of epilepsy and neurodegenerative conditions, an aging worldwide populace, the extended application of symptomatic neurological medications, the broadening of hospital-based neurological services, and higher rates of neurological disorder diagnoses.

The market for neurological disorder drugs is projected to experience robust expansion in the coming years. Its valuation is set to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth throughout the forecast period stems from various factors, including progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s diseases, enhanced availability of neurological care in developing markets, a growing need for tailored neurology treatments, and the wider availability of homecare and outpatient neurological therapies. Key trends during this period encompass the increasing uptake of disease-modifying neurological treatments, a heightened emphasis on prompt diagnosis and sustained disease management, an escalating requirement for combination drug therapies, the broadening scope of oral and home-based neurological interventions, and a stronger focus on managing symptoms and enhancing the quality of life for patients.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Growth Factors Are Strengthening The Neurological Disorder Drugs Market Landscape?

The rising occurrence of neurological conditions is anticipated to boost the expansion of the neurological disorder drugs market in the future. Neurological disorders are defined as ailments impacting the brain, spinal cord, and nerves, stemming from structural, biochemical, or electrical irregularities, which result in diverse symptoms. The increase in neurological illnesses is linked to the worldwide aging population and heightened exposure to environmental, metabolic, and lifestyle risk elements. Medications for neurological disorders are crucial in managing these intricate conditions, providing symptom alleviation, retarding disease advancement, and enhancing long-term patient prognoses. As an illustration, in September 2024, data from the Australian Institute of Health and Welfare, a government body based in Australia, indicates that the population suffering from dementia in Australia is predicted to more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, affecting about 315,500 men and 533,800 women. Consequently, the expanding incidence of neurological ailments is fueling the growth of the neurological disorder drugs market.

Which Segment-Based Categories Are Covered In The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Which Trends Are Expected To Shape The Neurological Disorder Drugs Market?

Leading companies in the neurological disorder drugs market are focusing on developing innovative solutions, such as Ocrelizumab-based therapies, to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, approximately 10-minute subcutaneous injection, marking the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.

Who Are The Businesses Driving Activity In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Neurological Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Holds The Largest Share In The Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurological Disorder Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Neurological Disorder Drugs Market Be By 2030 Compared To Its 2026 Market Size?

The neurological disorder drugs market size has demonstrated significant growth in recent years. It is anticipated to expand from $89.24 billion in 2025 to $94.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historical period’s growth can be ascribed to the increasing prevalence of epilepsy and neurodegenerative diseases, an aging global population, the continued use of symptomatic neurological drugs, the broadening of hospital-based neurological care, and enhanced diagnosis rates of neurological disorders.

The neurological disorder drugs market size is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $116.27 billion, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is attributable to several factors, including progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, enhanced availability of neurological care in developing markets, an escalating need for individualized neurology treatments, and the wider availability of homecare and outpatient neurological therapies. Key trends projected for the forecast period encompass a greater uptake of disease-modifying neurological therapies, an increasing emphasis on prompt diagnosis and sustained disease management, a heightened requirement for combination drug treatments, the broadening scope of oral and home-based neurological interventions, and a stronger focus on alleviating symptoms and enhancing patients’ quality of life.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Primary Drivers Are Shaping The Neurological Disorder Drugs Market?

The increasing incidence of neurological diseases is poised to stimulate the expansion of the neurological disorder drugs market in the coming years. Neurological disorders are conditions affecting the brain, spinal cord, and nerves, stemming from structural, biochemical, or electrical irregularities that manifest in various symptoms. The rise in these diseases is attributed to a growing global elderly population and heightened exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs are vital in addressing these complex conditions, offering symptom alleviation, slowing disease progression, and enhancing long-term patient well-being. For example, according to the Australian Institute of Health and Welfare in September 2024, it is forecasted that the number of individuals with dementia in Australia will more than double between 2023 and 2058, rising from approximately 411,100 in 2023 to 849,300 by 2058, impacting around 315,500 men and 533,800 women. This growing prevalence of neurological diseases is thus a key driver for the neurological disorder drugs market.

What Are The Different Segment Types In The Neurological Disorder Drugs Market Segment Breakdown?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Influencing The Neurological Disorder Drugs Market?

Leading companies within the neurological disorder drugs market are concentrating on advancing innovative remedies, such as those derived from Ocrelizumab, to elevate treatment efficacy, achieve better patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab itself is a humanized monoclonal antibody specifically engineered to target CD20-positive B cells, thereby contributing to a reduction in disease activity and a deceleration of progression in both relapsing and primary progressive forms of multiple sclerosis. For example, in September 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, secured regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This formulation is a twice-yearly, approximately 10-minute subcutaneous injection, representing the first-ever subcutaneous Ocrevus version to gain approval for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This upgraded delivery option is intended to boost convenience, widen access to the therapy, and support clinical workflow efficiency by providing a quicker, non-intravenous method of administration.

Who Are The Well-Known Companies In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Get The Full Neurological Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Where Is The Neurological Disorder Drugs Market Most Concentrated Geographically?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurological Disorder Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Neurological Disorder Drugs Market Projected To Become By 2030 Based On Its 2026 Valuation?

The neurological disorder drugs market has experienced substantial growth in recent years. This market is set to expand from $89.24 billion in 2025 to $94.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historical growth witnessed in this sector can be primarily attributed to the increasing incidence of epilepsy and neurodegenerative conditions, the aging global populace, the ongoing use of symptomatic neurological medications, the broadened provision of hospital-based neurological services, and improved diagnosis rates for neurological disorders.

The neurological disorder drugs market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This expansion during the forecast period is driven by improvements in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, enhanced availability of neurological care in developing markets, a growing need for tailored neurology treatments, and the wider provision of homecare and outpatient neurological therapy. Key developments expected during this period involve the increasing integration of disease-modifying neurological treatments, a heightened focus on prompt diagnosis and sustained disease management, an escalating requirement for combined drug therapies, the broader availability of oral and home-based neurological interventions, and a greater emphasis on mitigating symptoms and enhancing patient quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Primary Drivers Are Shaping The Development Of The Neurological Disorder Drugs Market?

The rising occurrence of neurological diseases is anticipated to boost the expansion of the neurological disorder drugs market in the future. Neurological disorders encompass conditions affecting the brain, spinal cord, and nerves, arising from structural, biochemical, or electrical abnormalities that lead to various symptoms. This increase in neurological diseases is linked to an aging global demographic and greater exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are crucial for managing these intricate conditions, offering symptomatic relief, slowing disease progression, and enhancing patients’ long-term prognoses. As an illustration, the Australian Institute of Health and Welfare, a government body based in Australia, reported in September 2024 a projection that the number of individuals living with dementia in Australia will more than double from approximately 411,100 in 2023 to 849,300 by 2058, affecting around 315,500 men and 533,800 women. Consequently, the growing frequency of neurological illnesses is propelling the advancement of the neurological disorder drugs market.

What Segment Groups Are Identified Within The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Advancing Progress In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are focusing on developing innovative solutions such as Ocrelizumab-based therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), which is a twice-yearly, approximately 10-minute subcutaneous injection. This marked the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.

Which Companies Hold Significant Positions In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Read the full neurological disorder drugs market report here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

How Does The Neurological Disorder Drugs Market Perform Across Major Global Regions?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurological Disorder Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurological disorder drugs market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Neurological Disorder Drugs Market by the end of 2030?

The neurological disorder drugs market size has experienced robust expansion in recent years. Projections indicate an increase from $89.24 billion in 2025 to $94.49 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. This historical growth can be linked to several key factors, including the increasing occurrence of epilepsy and neurodegenerative conditions, a globally aging population, the sustained usage of symptomatic neurological medications, the broadened availability of hospital-based neurological services, and improved detection rates for neurological disorders.

The neurological disorder drugs market is projected to experience substantial expansion over the upcoming years. This market is set to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, improved availability of neurological care in emerging markets, a growing need for personalized neurology treatments, and the expansion of homecare and outpatient neurological therapy. Key trends for the forecast period encompass the increasing embrace of disease-modifying neurological therapies, a heightened focus on early diagnosis and ongoing disease management, a surge in demand for combination drug therapies, the proliferation of oral and home-based neurological treatments, and a greater emphasis on symptom alleviation and enhancing the quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Drivers Are Shaping Future Opportunities In The Neurological Disorder Drugs Market?

The escalating occurrence of neurological diseases is anticipated to drive the growth of the neurological disorder drugs market in the future. Neurological disorders encompass conditions impacting the brain, spinal cord, and nerves, arising from structural, biochemical, or electrical abnormalities, which lead to diverse symptoms. The rise in neurological diseases can be attributed to an aging global population and increased exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are crucial in managing these complex conditions, offering symptomatic relief, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Consequently, the rising prevalence of neurological disease is fueling the expansion of the neurological disorder drugs market.

Which Segments Are Gaining Traction In The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Reshaping The Dynamics Of The Neurological Disorder Drugs Market?

Leading companies in the neurological disorder drugs market are actively engaged in developing innovative solutions, such as Ocrelizumab-based therapies, to enhance treatment effectiveness, improve patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody specifically engineered to target CD20-positive B cells, thereby assisting in the reduction of disease activity and the deceleration of progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, obtained regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This product is a twice-yearly, approximately 10-minute subcutaneous injection, marking it as the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This advanced delivery option is designed to improve patient convenience, expand access to therapy, and bolster clinical workflow efficiency by offering a quicker, non-intravenous administration method.

Who Are The Top-Performing Companies In The Neurological Disorder Drugs Market In Recent Years?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurological Disorder Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the water-soluble vitamin and mineral feed supplements market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Water-Soluble Vitamin And Mineral Feed Supplements Market?

The neurological disorder drugs market has shown strong growth in recent years. It is forecast to increase from $84.6 billion in 2024 to $89.24 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to factors such as increased animal testing producing promising results, a rise in therapeutic treatments, the growing incidence of neurological problems, governmental initiatives, and an increase in healthcare expenditure.

The neurological disorder drugs market size is expected to experience robust expansion in the coming years. It is projected to reach $110.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period can be attributed to the increasing array of therapeutic options and personalized therapies, a stronger focus on disease-modifying treatments, the expanding utilization of digital biomarkers, and the rising prevalence of neurological diseases. Key trends anticipated in the forecast period include progress in drug design, advancements in neuroimaging, breakthroughs in genetic research, strategic collaborations and licensing agreements, and the emergence of regenerative medicine.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Growth Drivers Are Propelling The Water-Soluble Vitamin And Mineral Feed Supplements Market?

The future expansion of the neurological disorder drugs market is anticipated due to the rising occurrence of neurological diseases. These conditions, which involve structural, biochemical, or electrical irregularities affecting the brain, spinal cord, and nerves, manifest in various symptoms. The escalating incidence of neurological diseases can be linked to an aging global population and increased susceptibility to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders are essential in managing these intricate conditions, providing symptom alleviation, slowing disease advancement, and enhancing long-term patient prognoses. For example, the Australian Institute of Health and Welfare, an Australia-based government entity, projected in September 2024 that the population affected by dementia in Australia will more than double from approximately 411,100 in 2023 to 849,300 by 2058, impacting about 315,500 men and 533,800 women. Consequently, the growing prevalence of neurological diseases is a key factor boosting the neurological disorder drugs market.

Which Segmentation Factors Are Most Significant In The Water-Soluble Vitamin And Mineral Feed Supplements Market Analysis?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What New Opportunities Are Emerging From Trends In The Water-Soluble Vitamin And Mineral Feed Supplements Market?

Leading companies in the neurological disorder drugs market are concentrating on developing advanced Ocrelizumab drug therapies to improve treatment efficacy, enhance patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody utilized as a therapeutic agent for multiple sclerosis (MS), a type of neurological disorder. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced Ocrevus (Ocrelizumab) in India, presenting a new disease-modifying therapy (DMT) for multiple sclerosis. Drawing on over 10 years of clinical and real-world data, Ocrevus stands as the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This monoclonal antibody specifically targets CD20-positive B cells, which are believed to contribute to the autoimmune assault on the central nervous system in multiple sclerosis (MS). Ocrevus is prescribed for treating both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it the inaugural drug approved for both forms of the illness. It is given intravenously, typically every six months, and clinical trials have demonstrated its effectiveness in lessening disease activity and slowing disability progression.

Who Are The Most Influential Companies In The Water-Soluble Vitamin And Mineral Feed Supplements Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Holds The Largest Share In The Water-Soluble Vitamin And Mineral Feed Supplements Market Today?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Water-Soluble Vitamin And Mineral Feed Supplements Market 2025, By The Business Research Company

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurological Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Neurological Disorder Drugs Market Today And What Is Its Future Size?

In recent times, the market size for drugs related to neurological disorders has seen substantial growth. It is projected to rise from $84.6 billion in 2024 to $89.24 billion in 2025, registering a compound annual growth rate (CAGR) of 5.5%. The past growth can be associated with an escalation in animal testing yielding promising outcomes, an uptick in therapeutic treatments, increase in neurological issues, government-led initiatives, and an upsurge in healthcare spending.

Expectations are high for strong growth within the neurological disorder drugs market over the approaching years, with a projected increase to “$110.99 billion by 2029, showcasing a compound annual growth rate (CAGR) of 5.6%. This advancement during this period can be credited to the expansion of tailored therapies and therapeutic options, an increased focus on treatments aimed towards disease modification, digital biomarkers’ growing implementation, and an overall rise in neurological disease incidence. In the forecast period, impactful trends include drug design enhancements, progress in neuroimaging, breakthroughs in genetics research, collaborative efforts and licensure agreements, and the burgeoning field of regenerative medicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What External And Internal Drivers Are Influencing The Neurological Disorder Drugs Market?

The surge in neurological diseases is anticipated to boost the expansion of the neurological disorder drugs market. Neurological disorders are conditions that affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, resulting in various symptoms. The augmentation of neurological diseases is ascribed to the aging global populace along with increased exposure to environmental, metabolic, and lifestyle hazards. Neurological disorder drugs are integral in handling these intricate conditions, providing symptom relief, slowing the course of the illness, and enhancing patient’s long-term prognosis. For example, in September 2024, as per the Australian Institute of Health and Welfare, a governmental agency based in Australia, it’s projected that the number of dementia patients in Australia will more than double from 2023 to 2058, advancing from about 411,100 in 2023 to 849,300 by 2058, with approximately 315,500 men and 533,800 women affected. Consequently, the escalating prevalence of neurological disease is fueling the growth of the neurological disorder drugs market.

How Is The Neurological Disorder Drugs Market Organized By Different Segments?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Current And Upcoming Trends Are Shaping The Neurological Disorder Drugs Market?

Major entities in the neurological disorder drugs market are concentrating on the creation of novel Ocrelizumab drug treatments to boost the effectiveness of therapy, better patient results, and extend treatment choices for those suffering from multiple sclerosis. Used in treating this type of neurological disorder, Ocrelizumab is a monoclonal antibody that has been humanized. To exemplify, in February 2024, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced Ocrevus (Ocrelizumab), a groundbreaking disease-modifying therapy (DMT) drug to treat multiple sclerosis in India. Ocrevus made history as the first-ever approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) based on more than a decade of clinical and real-world evidence. This monoclonal antibody specifically targets CD20-positive B cells which are suspected to be involved in the autoimmune attack on the central nervous system in cases of multiple sclerosis (MS). Ocrevus treats both RRMS and PPMS, positioning it as the first drug to be approved for both disease types. Given intravenously, typically biannually, Ocrevus has demonstrated its effectiveness in diminishing disease activity and slowing down disability progression during clinical trials.

Who Are The Most Influential Companies In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Dominates The Neurological Disorder Drugs Market Today?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Water-Soluble Vitamin And Mineral Feed Supplements Industry?

The market for drugs targeting neurological disorders has seen a robust expansion in recent years. It is set to escalate from $84.6 billion in 2024 to $89.24 billion in 2025, marking a compound annual growth rate (CAGR) of 5.5%. The surge in this historical phase is due to factors such as increased animal testing yielding optimistic results, a rise in therapeutic interventions, an upsurge in neurological issues, governmental strategies, and expanded healthcare outlay.

The market for drugs treating neurological disorders is expected to witness a robust expansion in the coming years. It’s projected to increase to “$110.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The promising growth during the forecast period can be attributed to the evolution of therapeutic alternatives, personalization of therapies, an increasing emphasis on disease-modifying treatment, wider application of digital biomarkers, and the rising occurrence of neurological ailments. Key trends projected during the forecast period comprise development in drug design, enhancement in neuroimaging, progress in genetic research, various collaboration and licensing deals, and the advent of regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

#Which Factors Are Currently Driving The Growth Of The Water-Soluble Vitamin And Mineral Feed Supplements Market?

The escalating population of livestock is projected to fuel the expansion of the water-soluble vitamin and mineral feed supplements market. Livestock are animals that are raised or kept for various reasons, such as usage, pleasure, or profit, with a particular focus on farm-raised species. These animals, which include cattle, hogs, horses, poultry, sheep, and small animals, are bred and sustained by agricultural producers. These livestock can be given water-soluble vitamin and mineral nutritional supplements for purposes such as healthy bone development and maintaining reproductive efficiency. For example, as reported by Eurostat in March 2023, the statistical office based in Luxembourg indicated an increase of 330,000 pigs in Italy’s population from November to December 2022 – a 4% rise compared to 2021. Also, Sweden experienced a growth in their pig population by 50,000 heads, or a 3% increase from the prior year. In summary, the European Union held a considerable livestock population in May 2022, estimated at 142 million pigs, 76 million cattle, 60 million sheep, and 11 million goats. This rise in livestock population is henceforth triggering the growth of the water-soluble vitamin and mineral feed supplements market.

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Long-Term Trends Are Likely To Affect The Water-Soluble Vitamin And Mineral Feed Supplements Market?

Leading enterprises in the neurological disorder drugs sector are heavily investing in the innovation of Ocrelizumab drug therapies. Their aim is to improve the effectiveness of treatments, boost patient results, and offer more choice for individuals afflicted with multiple sclerosis. Ocrelizumab, a humanized monoclonal antibody, is utilized as a medicinal drug in treating multiple sclerosis (MS), a form of neurological disorder. As an illustration, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced Ocrevus, an Ocrelizumab-based disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India in February 2024. Ocrevus stands as the premiere and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), driven by a decade’s worth of clinical and real-world data. This monoclonal antibody takes aim at CD20-positive B cells, known for their role in the autoimmune assault on the central nervous system in multiple sclerosis (MS) cases. Ocrevus has been approved for the treatment of both RRMS and PPMS, setting a precedent as the first drug approved for both forms of the disease. This drug is delivered intravenously, usually biannually, and has proven effective in curtailing disease activity and slowing down disability progression in clinical trials.

Who Are The Main Participants Shaping The Water-Soluble Vitamin And Mineral Feed Supplements Market Landscape?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Water-Soluble Vitamin And Mineral Feed Supplements Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model